Abstracts tagged "Lupus nephritis"

Abstract Number: 2815 • 2016 ACR/ARHP Annual Meeting
Comparison of Lupus Nephritis Induction Therapy with Cyclophosphamide High Dose Versus Low Dose
Juliana Valim¹, Verônica Lima², Fernanda Guimarães³, Fernanda Chaer⁴ and Branca Souza⁵, ¹Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, ²Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil, ³Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, ⁵Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil
Background/Purpose: To Compare the induction therapy of lupus nephritis with cyclophosphamide (CYC) high dose or low dose and identify possible predictors of disease remission. Methods:…
Abstract Number: 2824 • 2016 ACR/ARHP Annual Meeting
Lack of Partial Renal Response By 12 Weeks after Induction Therapy Is an Indicator to Switch the Treatment in Lupus Nephritis Class III or IV for Reducing Future Damage Accrual
Hironari Hanaoka¹, Hidehiro Yamada², Tomofumi Kiyokawa³, Harunobu Iida¹, Takeshi Suzuki¹, Yoshioki Yamasaki⁴, Seido Ooka⁵, Hiroko Nagafuchi³, Takahiro Okazaki³, Daisuke Ichikawa⁶, Sayuri Shirai⁶, Yugo Shibagaki⁷, Junki Koike⁸ and Shoichi Ozaki³, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, ³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁶Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁷Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, K, Japan, ⁸Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. The guideline or recommendation for…
Abstract Number: 2827 • 2016 ACR/ARHP Annual Meeting
Prognostic Significance of Repeat Biopsy in Lupus Nephritis: Histopathologic Worsening Is an Independent Risk Factor for End Stage Renal Disease and Death
Cristina Arriens¹, Sixia Chen², David Karp³, Ramesh Saxena⁴, Kamalanathan Sambandam⁴, Eliza Chakravarty¹, Judith A. James⁵ and Joan T. Merrill⁶, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Internal Medicine/Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Approximately half of SLE patients develop lupus nephritis (LN), a major cause of morbidity and early mortality. It is known that prolonged renal inflammation…
Abstract Number: 2829 • 2016 ACR/ARHP Annual Meeting
Adherence to Treatment and Renal Transplantation Graft Failure in Lupus Nephritis
Eleana Ntatsaki¹, Alba Velo Garcia², Alan D. Salama³ and David A. Isenberg⁴, ¹Centre for Rheumatology, University College London, London, United Kingdom, ²Internal Medicine Department, University Hospital Complex of Pontevedra, Pontevedra, Spain, ³Centre for Nephrology, University College London, London, United Kingdom, ⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Patient non-adherence has been reported as a potential adverse outcome predictor in renal transplantation (rTp) for patients with lupus nephritis (LN). We investigated potential…
Abstract Number: 2842 • 2016 ACR/ARHP Annual Meeting
Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis
William Fung¹, Jiandong Su² and Zahi Touma³, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) manifests with proteinuria and/or active urine sediment. Renal composite indices include proteinuria, urinary active sediment (RBCs, casts) and serum creatinine.…
Abstract Number: 746 • 2016 ACR/ARHP Annual Meeting
Discrepancy in Rituximab-Induced B-Cell Depletion in Peripheral Blood and the Kidney and Relationship with Clinical Response in Patients with Lupus Nephritis
Ruth J. Pepper¹, Venkat Reddy², Scott Henderson³ and Maria J. Leandro⁴, ¹UCL Centre for Nephrology, Royal Free Hospital, London, United Kingdom, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³UCL Centre for Nephrology, University College London, London, United Kingdom, ⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Patients with lupus nephritis (LN) achieve variable clinical response following Rituximab (RTX) based B-cell depletion therapy, with rituximab treatment aiming to decrease the use…
Abstract Number: 2852 • 2016 ACR/ARHP Annual Meeting
Long Term Prognosis of Lupus Nephritis in the Afro-Caribbean Population of Martinique with Free Access to Healthcare
Aymeric Couturier¹, Vincent Molinie², Charles Cartou³, Serge ARFI⁴, Violaine Emal-Aglae⁵, Katlyne Polomat⁶, Florence MOINET⁶, Georges JEAN BAPTISTE⁷ and Christophe Deligny⁸, ¹nephrology, Pierre Zobda Quitman hospital, Fort de France, Martinique, ²Pathology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, ³nephrology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, ⁴University Hospital, CHU Fort de France, Fort de France, Martinique, ⁵Nephrology, Centre Hospitalier de Mangot-Vulcin, Le Lamentin, Martinique, ⁶Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort de France, Martinique, ⁷RHEUMATOLOGY, CHU MARTINIQUE, FWI, Fort-de-France, Martinique, ⁸Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique
Background/Purpose: In African-descent patients, lupus nephritis (LN) lead to a worse outcome than in Caucasians. Long term data are rare in countries where black populations…
Abstract Number: 749 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Efficacy, Safety, and Tolerability of BIIB023 As an Adjunct to Standard of Care in Subjects with Lupus Nephritis
Richard Furie¹, Ana Malvar², Sandra V. Navarra³, Karen Smirnakis⁴, Jessica Kong⁴, Nathalie Franchimont⁴ and Fei Shih⁴, ¹Division of Rheumatology, North Shore LIJ Health System, Great Neck, NY, ²Nephrology Division, Hospital Fernandez, Buenos Aires, Argentina, ³Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ⁴Biogen, Cambridge, MA
Background/Purpose: The addition of an anti-TWEAK monoclonal antibody to SOC LN therapy did not improve 52-week RR rates in proliferative LN despite observed pharmacodynamic effects.…
Abstract Number: 2855 • 2016 ACR/ARHP Annual Meeting
The Long-Term Clinical Outcomes of Lupus Nephritis
Julie Davidson¹, Qinggong Fu², Beulah Ji³, Sapna Rao⁴, David Roth⁵, Laurence S Magder⁶ and Michelle Petri⁷, ¹Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, United Kingdom, ²Worldwide Epidemiology, GlaxoSmithKline, Collegeville, PA, ³Clinical Development, GlaxoSmithKline R&D, Uxbridge, United Kingdom, ⁴Real World Evidence, GlaxoSmithKline R&D, Research Triangle Park, NC, ⁵GSK, Philadelphia, PA, ⁶Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ⁷Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Clinical trials in lupus nephritis have often been designed to demonstrate renal response (or remission) following therapy based on categorical remission endpoints (often no…
Abstract Number: 1180 • 2016 ACR/ARHP Annual Meeting
Class V Lupus Nephritis Results in Significant Numbers of End Stage Renal Disease and Death in a Population-Based Registry
Jennifer Brandt¹, Cristina Drenkard², Jason Cobb³, Gaobin Bao⁴ and S. Sam Lim⁴, ¹Department of Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Department of Nephrology, Emory University School of Medicine, Atlanta, GA, ⁴Medicine, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Although the diagnosis of pure class V lupus nephritis (LN) is generally thought to portend a favorable prognosis, outcomes on a population-level are not…
Abstract Number: 3104 • 2016 ACR/ARHP Annual Meeting
Early Proteinuria Response in Real Life Situation Predicts Long-Term Lupus Renal Outcome in Ethnically Diverse Group with Biopsy-Proven Nephritis
Michelle Lopes¹, Luciana Seguro¹, Maite Castro², Danielle Daffre³, Eduardo Ferreira Borba² and Eloisa Bonfa⁴, ¹Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ³São Paulo University, São Paulo, Brazil, ⁴Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil
Background/Purpose: Treat to target strategies are becoming the best approach for several rheumatic disorders. Recently retrospective analyses of two important lupus trials have reported that…
Abstract Number: 1394 • 2016 ACR/ARHP Annual Meeting
A Pilot Study of Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis
Jennifer C. Cooper¹, B. Anne Eberhard², Marilynn Punaro³, Stacy P. Ardoin⁴, Hermine I. Brunner⁵, Joyce Hsu⁶, Linda Wagner-Weiner⁷, Kelly Rouster-Stevens⁸, Laura E. Schanberg⁹, Marisa Klein-Gitelman¹⁰, Emily von Scheven¹¹ and CARRA Registry Investigators, ¹Pediatrics, Divison of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Cohen Children's Medical Center of New York, New Hyde Park, NY, ³Texas Scottish Rite Hospital for Children, Dallas, TX, ⁴Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ⁵Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁷Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁸Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁹Pediatrics, Duke Medical Center, Durham, NC, ¹⁰Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ¹¹Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA
Background/Purpose: Childhood-onset systemic lupus erythematous (cSLE) patients are at higher risk for renal disease than those with adult-onset disease. Mycophenolate mofetil (MMF) and intravenous…
Abstract Number: 1778 • 2015 ACR/ARHP Annual Meeting
Disease Progression Is Altered By Moderate Exercise and Social Stress in a Murine Model of Lupus Nephritis
Jeffrey Hampton¹, Nicholas A. Young², Sudha Agarwal³, Saba Aqel³, Kendra Jones³, Lai-Chu Wu^2,4, Nicole Powell⁵, John Sheridan⁵, Michael Bruss³ and Wael N. Jarjour², ¹Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Biological Chemistry and Pharmacology, The Ohio State University College of Medicine, Columbus, OH, ⁵Institute for Behavioral Medicine Research, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Chronic inflammation is pathognomonic of autoimmune diseases and contributes to organ damage. Our group has previously shown that moderate daily exercise reduces systemic inflammation…
Abstract Number: 1781 • 2015 ACR/ARHP Annual Meeting
Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Young Ho Lee and Gwan Gyu Song, Rheumatology, Korea University Medical Center, Seoul, South Korea
Background/Purpose: Cyclophosphamide (CYC) regimens improved renal outcomes, and have long been considered the gold standard for inducing renal remission and preventing renal flares in proliferative…
Abstract Number: 1809 • 2015 ACR/ARHP Annual Meeting
Real Life Implementation of Lupus Nephritis Randomized Controlled Trials
Angela Pakozdi¹, Ravindra Rajakariar², Muhammad Magdi Yaqoob² and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Randomized controlled trials (RCTs) are the gold standard for assessing treatment efficacy. However, due to their often strict design, generalization of research results to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].